HSK16149
Phase 3Small molecule
Haisco Pharmaceutical Group Co., Ltd.HSK16149 is one of 47 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
1
Indications
10
Total Trials
2
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Neuropathic Pain
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cymbalta
Jazz PharmaceuticalsApproved
Trileptal
NovartisApproved
Neurontin
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Aricept
EisaiApproved
Savella
AbbVieApproved
Lioresal
NovartisApproved
Calciferol
Jazz PharmaceuticalsApproved
Marinol
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuralgia3 trials
Neuropathic Pain3 trials
Interaction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HSK16149. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details